Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31133376 | 1.00 | DRD2 (0.34) | DRD2DRD3GRIN1GRIN2BHSD11B1 | |
| SCHEMBL29467508 | 0.86 | DRD2 (0.36) | DRD2DRD3GRIN1GRIN2BHSD11B1 | |
| SCHEMBL2054541 | 0.86 | DRD2 (0.36) | DRD2DRD3GRIN1GRIN2BHSD11B1 | |
| SCHEMBL10146421 | 0.80 | — | — | |
| SCHEMBL31069046 | 0.80 | — | — | |
| SCHEMBL17413659 | 0.75 | DRD2 (0.42) | DRD2DRD3GRIN1GRIN2BGRIN2D | |
| SCHEMBL8348677 | 0.75 | — | — | |
| SCHEMBL13028729 | 0.73 | — | — | |
| SCHEMBL31647978 | 0.73 | — | — | |
| SCHEMBL17781302 | 0.73 | TIPARP (0.31) | DRD2DRD3TIPARP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4711364-A1 | FUSED PYRROLE RING OR FUSED PYRIDINE RING COMPOUND | Pharmaengine, Inc. (TW) | 2026-03-18 | — | — | EP | disclosed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| WO-2025134078-A1 | ORGANIC COMPOUNDS AS MUSCARINIC M4 RECEPTOR POSITIVE ALLOSTERIC MODULATORS (M4 PAMS) | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-06-26 | — | — | WO | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| EP-2041073-A1 | CXCR2 INHIBITORS | Sanofi-Aventis (FR) | 2009-04-01 | — | — | EP | disclosed |
| US-7501435-B2 | Inhibitors of checkpoint kinases | MERCK & CO., INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501435-B2 | Inhibitors of checkpoint kinases | MERCK & CO., INC. (US) | 2009-03-10 | — | — | US | disclosed |
| WO-2008000410-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008000409-A1 | NEW CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | disclosed |
| WO-2007127138-A1 | TRIAZOLOQUINAZOLINONE DERIVATIVES AS INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070254879-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2007-11-01 | — | — | US | disclosed |
| US-20070254879-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2007-11-01 | — | — | US | disclosed |
| WO-2007015837-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007008502-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254879-A1 | Inhibitors of checkpoint kinases | CHEK1, CHEK2, PLK1 | DRD2 4387/4885DRD3 4355/4885GRIN1 4079/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | DRD2 497/4885DRD3 295/4885GRIN1 516/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | DRD2 955/4885DRD3 1018/4885GRIN1 333/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | DRD2 955/4885DRD3 1018/4885GRIN1 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.